RLMD · Relmada Therapeutics, Inc. · Metrics
$3.36
+0.20 (+6.33%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$358.41M
Shares
106.67M
Volume · Oct 20
740.29K
Avg daily vol (3M)
1.26M
RLMD metrics
62 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$3.36
Market cap
$358.41M
Price action
20 metricsPrice change (1W)
+0.0%
Price change (30D)
-19.2%
Price change (3M)
-36.6%
Price change (6M)
-52.9%
Price change (YTD)
-30.4%
Price change (1Y)
+48.7%
Trailing year
Price change (5Y)
-85.7%
52-week high
$7.86
52-week low
$2.10
Change from 52-week high
-57.3%
Change from 52-week low
+60.0%
Annualized volatility
97.5%
Annualized volatility (3M)
57.8%
Beta
1.7
RSI (14D)
40.5
Price vs SMA 50
-17.4%
Price vs SMA 200
-37.7%
Avg volume (3M)
1.26M
Relative volume
0.6
Average dollar volume
$5.47M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
106.67M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
106,467.7×
reciprocal yield 0.0%
P / book
1.6
reciprocal yield 61.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
14.9%
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$473
Operating profit (TTM)
−$65.13M
Net income (TTM)
−$61.93M
Trailing 12 months
Diluted EPS (TTM)
$-0.90
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$3,166
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+238.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-30.0%
Return on assets
-28.3%
Debt / equity
—
Current ratio
29.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
29.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$217.73M
Latest balance sheet
Cash & equivalents
$11.33M
Total assets
$219.06M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$45.99M
Capital expenditures (TTM)
—
R&D (TTM)
$28.59M
SG&A (TTM)
—
Stock compensation (TTM)
$8.74M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
127
13F filer change QoQ
+23
Institutional ownership
94.2%
Conviction holders (share of 13F filers)
3.2%
Crowding (high-turnover and private-fund holders)
58.1%
Private-fund adviser ownership
56.1%
Active holders' share change QoQ
+3.4%
Holder tenure
5.0
Price vs estimated holder cost
+51.8%
Ownership (registered funds)
1 metricsIndex-fund ownership
9.4%
Short interest
3 metricsShort interest
12.6%
Latest settlement · 13.0 days to cover
Days to cover
13.0d
Short-squeeze score
59 / 100
Insider activity
2 metricsNet insider buying (90D)
$1.67M
Insider-sentiment score
93 / 100
Risk flags
1 metricsGoing concern
—